Latest News
Aritzia’s Upbeat Earnings Point to Resilient Consumers: 2 Canadian Retail Stocks to Considerfool.ca
Aritzia offers higher growth upside while North West provides defensive income exposure. Different investors might want them for different reasons.
Via The Motley Fool · October 27, 2026
NXP (NXPI) Q3 2026 Earnings Call Transcriptfool.com
Automotive revenue topped $2B for first time as SDV adoption accelerates.
Via The Motley Fool · October 27, 2026
Manhattan Associates (MANH) Q3 2026 Earnings Call Transcriptfool.com
Cloud revenue hit parity with services as AI pilots converted at 100% rates.
Via The Motley Fool · October 27, 2026
History Says the Stock Market's Best 6 Months Start Nov. 1. Here's How Often They've Paid Off Since 1950.fool.com
The index has climbed in most of these stretches since 1950. What did the misses cost?
Via The Motley Fool · October 27, 2026
Why Brown & Brown Stock Slumped by 5% Todayfool.com
Its latest quarterly earnings report wasn't greeted warmly by the market.
Via The Motley Fool · October 27, 2026
Investing $1,000 in Each of These 3 Stocks 20 Years Ago Would Have Created a Portfolio Worth $674,000 Todayfool.com
You don't need a ton of money to generate significant returns in the stock market.
Via The Motley Fool · October 27, 2026
S&P Global: 3 Key Takeaways for Long-Term Investorsfool.com
AI annual contract values grew by 1.8x compared with those of non-AI customers in the market intelligence division.
Via The Motley Fool · October 27, 2026
S&P Global vs. Toast: Which Financial Stock Is a Better Buy in 2026?fool.com
S&P Global commands a 29% net margin and $5.5B in free cash flow, while Toast is growing 24% annually with zero debt and a 2.4x P/S valuation.
Via The Motley Fool · October 27, 2026
Why Cerebras Systems Stock Jumped on Tuesdayfool.com
The company announced a groundbreaking partnership.
Via The Motley Fool · October 27, 2026
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1bmarketbeat.com
Aclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic dermatitis and asthma. The company said the treatment was well tolerated and
Via MarketBeat · October 27, 2026
Public Storage Q3 Earnings Call Highlightsmarketbeat.com
Public Storage (NYSE:PSA) raised its 2026 outlook for the second time this year after reporting third-quarter operating results that exceeded its expectations, citing stronger customer retention, improved new-customer pricing and a slowing pace of new self-storage supply.
Core funds from operations
Via MarketBeat · October 27, 2026
What Polaris (PII) Said on Its Q3 Earnings Callmarketbeat.com
Polaris (NYSE:PII) reported third-quarter results that exceeded its expectations, supported by growth in utility-oriented off-road vehicles, commercial and government demand, parts and accessories, marine products, and seasonal vehicles. The company raised its full-year outlook for the third time in
Via MarketBeat · October 27, 2026
What Pentair (PNR) Said on Its Q3 Earnings Callmarketbeat.com
Pentair (NYSE:PNR) reported third-quarter 2026 adjusted earnings per share of $1.18, exceeding its guidance range of approximately $1.05 to $1.08, as performance in its Flow and Water Solutions segments helped offset lower Pool sales tied to a channel inventory reduction.
Third-quarter sales were $
Via MarketBeat · October 27, 2026
What Nucor (NUE) Said on Its Q3 Earnings Callmarketbeat.com
Nucor (NYSE:NUE) reported its strongest quarterly performance in more than three years for the third quarter of 2026, citing record steel shipments, improved pricing and contributions from recently completed investments. The company generated net earnings of $1.3 billion, or $5.80 per share, and app
Via MarketBeat · October 27, 2026
What Novartis (NVS) Said on Its Q3 Earnings Callmarketbeat.com
Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.
Chief Executive Officer Vas Narasimhan said quarterly sales rose 4% in constant curre
Via MarketBeat · October 27, 2026
Piedmont Realty Trust Q3 Earnings Call Highlightsmarketbeat.com
Piedmont Realty Trust (NYSE:PDM) reported third-quarter results marked by higher leasing volumes, rising rental rates, portfolio recycling activity and a refinancing that reduced its weighted average debt cost. The office real estate investment trust also raised and narrowed its full-year core funds
Via MarketBeat · October 27, 2026
What Gerdau (GGB) Said on Its Q3 Earnings Callmarketbeat.com
Gerdau (NYSE:GGB) reported third-quarter 2026 EBITDA of BRL 3.8 billion and an EBITDA margin of 20.2%, its highest margin since the second quarter of 2023, as strong North American demand and operating performance offset continued pressure in Brazil.
Adjusted net income reached BRL 1.5 billion, whi
Via MarketBeat · October 27, 2026
Noble Q3 Earnings Call Highlightsmarketbeat.com
Noble (NYSE:NE) reported third-quarter 2026 adjusted EBITDA of $201 million on revenue of $684 million, as several rigs transitioned between contracts during the period. The offshore driller generated cash flow from operations of $144 million, spent $192 million on capital expenditures and recorded
Via MarketBeat · October 27, 2026
BigBear.ai Q3 Earnings Call Highlightsmarketbeat.com
BigBear.ai (NYSE:BBAI) reported third-quarter revenue growth of 31% year over year and raised its full-year 2026 revenue outlook, citing momentum in generative AI, national security and border-security contracts.
Revenue for the quarter totaled $43.6 million, while gross margin expanded to 31.2%, u
Via MarketBeat · October 27, 2026
National Research Q3 Earnings Call Highlightsmarketbeat.com
National Research (NASDAQ:NRC), which operates as NRC Health, reported third-quarter revenue growth of 11% to $38 million as a large customer implementation went live on schedule and contributed revenue for the full quarter.
CEO Trent Green said the company’s growth accelerated from 4% in the first
Via MarketBeat · October 27, 2026
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?fool.com
The biotech has experienced a pullback in recent weeks.
Via The Motley Fool · October 27, 2026
Celestica (CLS) Q3 2026 Earnings Call Transcriptfool.com
Revenue surged 83% as AI infrastructure demand accelerated across networking and compute.
Via The Motley Fool · October 27, 2026
NOV (NYSE:NOV) surprises with Q3 2026 sales
Oilfield equipment manufacturer NOV (NYSE:NOV) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 2.3% year on year to $2....
Via StockStory · October 27, 2026
Stock Market Today, Oct. 27: Boeing Plummets 11% on Lower Production Rates and Missed Delivery Targetsfool.com
On Oct. 27, 2026, the aerospace giant announced it would miss delivery targets and slashed its production targets, sending shares tumbling.
Via The Motley Fool · October 27, 2026
Monarch (NASDAQ:MCRI) misses Q3 2026 sales expectations
Luxury casino and resort operator Monarch (NASDAQ:MCRI) missed Wall Street’s revenue expectations in Q3 2026 as revenue rose 2.4% year on year to $146.3 mill...
Via StockStory · October 27, 2026
